Back

Do tafamidis and acoramidis improve survival and cardiovascular outcomes in transthyretin amyloid cardiomyopathy? a systematic review and meta-analysis

30 August 2026 (14:15 - 15:00)
Organised by: Logo
Congress Presentation Part of: Device treatment: artificial intelligence and left ventricular Risk Factors and Risk Assessment ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Elena Alupei

(Romania)

6 More presentations in this session

Presentation thumbnail
Circulating secretoneurin concentrations predict mortality and heart failure hospitalizations but not ventricular arrhythmias in stable ICD outpatients
Professor H. Rosjo (Nordbyhagen, NO)
Abstract
Presentation thumbnail
Intrinsic versus conventional antitachycardia pacing for ventricular tachycardia: a systematic review and meta-analysis
Doctor W. Gminski (Torun, PL)
Abstract
Presentation thumbnail
Incremental diagnostic value of left endomyocardial biopsy for non-ischemic left ventricular scar beyond imaging modalities
Doctor F. Schiavone (Ancona, IT)
Abstract
Presentation thumbnail
Artificial intelligence versus clinicians for ventricular fibrillation detection: hierarchical bivariate meta-analysis of 86,399 electrocardiograms
Doctor A. Rehman (Karachi, PK)
Abstract
Presentation thumbnail
Generalizing VEST trial results on wearable cardioverter-defibrillators to a Polish real-world cohort: an anchored transportability analysis
Doctor P. Mitkowski (Poznan, PL)
Abstract

Access the full session

Session thumbnail
Device treatment: artificial intelligence and left ventricular

The Event

Event poster

ESC Congress 2026

30 August 2026 14:15 CET
You may be interested in
thumbnail
Congress Presentation
Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy
29 June 2021
thumbnail
Congress Presentation
The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and prognostic meta-analysis
20 June 2025
thumbnail
Congress Presentation
Stabilizers of transthyretin in amyloid cardiomyopathy: a systematic review and meta-analysis.
11 May 2024
thumbnail
Congress Presentation
Beta-blocker exposure and long-term survival in patients with transthyretin amyloid cardiomyopathy.
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources